Cytovac is a growing Danish biotech company, which has chosen to focus on development of a cancer treatment that uses the body’s own immune system.
Promising results gained by the dedicated research team over a number of years, have brought about the development of the ALECSAT therapy. ALECSAT is a therapy based on injection of activated cells from the immune system to patients. These cells will attack the cancer cells and activate the immune system. As Cytovac solely apply the patient’s own cells, this therapy is gentle and without the side effects associated with existing cancer therapies.